Metastatic Bone Disease

Global Metastatic Bone Disease Market to Reach US$30.8 Billion by 2030

The global market for Metastatic Bone Disease estimated at US$20.9 Billion in the year 2024, is expected to reach US$30.8 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$12.3 Billion by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 6.4% CAGR

The Metastatic Bone Disease market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.2% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Metastatic Bone Disease Market - Key Trends & Drivers Summarized

Why Is the Treatment of Metastatic Bone Disease Becoming a Healthcare Priority?

Metastatic bone disease (MBD) has become an increasing healthcare focus due to its prevalence in patients with advanced cancers, particularly breast, prostate, and lung cancers. MBD occurs when cancer cells spread to bones, leading to symptoms like pain, fractures, and decreased mobility, significantly affecting patients’ quality of life. Treatment of MBD involves a multi-disciplinary approach, including pain management, radiotherapy, surgical interventions, and medications to strengthen bones. With an aging population and rising cancer incidences globally, the demand for effective MBD treatment solutions is critical for improving patient outcomes.

What Technological and Therapeutic Advancements Are Transforming MBD Treatment?

Innovations in therapeutic and imaging technologies are reshaping MBD treatment, allowing for more precise and effective care. Advances in radiopharmaceuticals and bone-targeting agents, such as bisphosphonates and denosumab, help in reducing bone resorption and managing pain, improving patient quality of life. Minimally invasive surgical techniques and advanced implants have also enabled better fracture stabilization, reducing recovery times and improving mobility. Furthermore, imaging technologies, including MRI and PET scans, allow for early detection and accurate assessment of bone metastases, facilitating timely interventions. These advancements provide healthcare providers with a broader range of tools to manage MBD effectively.

Which Patient Groups and Healthcare Sectors Are Most Impacted by MBD?

The patient groups most affected by metastatic bone disease are those with advanced stages of cancers, particularly breast, prostate, and lung cancers, which frequently metastasize to bone. Oncology departments and specialized orthopedic units within hospitals are at the forefront of MBD treatment, managing both the oncological and orthopedic aspects of the disease. Rehabilitation centers and palliative care facilities also play a crucial role in providing pain relief and mobility support for MBD patients. This multidisciplinary approach underscores the importance of comprehensive care for MBD, aimed at improving patients’ quality of life and mobility.

The Growth in the Metastatic Bone Disease Market Is Driven by Several Factors

The growth in the metastatic bone disease market is driven by several factors, including the increasing incidence of cancers, advancements in bone-targeted therapies, and the rising demand for supportive care solutions. The growing global cancer burden has expanded the need for MBD treatment options that alleviate pain and improve mobility. Innovations in therapeutics, such as radiopharmaceuticals and targeted bone-strengthening drugs, have provided more effective treatment options, enhancing patient outcomes. Additionally, the emphasis on palliative care and quality-of-life improvements for cancer patients has fueled the adoption of advanced MBD treatments, supporting market growth.

SCOPE OF STUDY:

The report analyzes the Metastatic Bone Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
End-Use (Hospitals, Specialty Clinics, Ambulatory Surgical Centers); Origin of Metastasis (Breast, Lung, Thyroid, Kidney, Prostate, Other Origin of Metastasis); Treatment (Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Amgen, Inc.
• Bayer AG
• Boston Scientific Corporation
• BTG PLC
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Fresenius Kabi AG
• Medtronic PLC
• Merck & Co., Inc.
• Novartis International AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.